Baseline observation carry forward: reasoning, properties, and practical issues.

PubWeight™: 1.13‹?› | Rank: Top 10%

🔗 View Article (PMID 20183433)

Published in J Biopharm Stat on July 01, 2009

Authors

Jun Shao1, David C Jordan, Yili L Pritchett

Author Affiliations

1: Department of Statistics, University of Wisconsin, Madison, Wisconsin 53706, USA. shao@cs.wisc.edu

Articles by these authors

A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med (2005) 1.99

The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain (2009) 1.63

Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol (2006) 1.08

An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med (2007) 0.93

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) (2011) 0.91

Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care (2007) 0.90

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol (2008) 0.87

Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist. J Pharmacokinet Pharmacodyn (2005) 0.87

Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays. J Biomol Screen (2012) 0.81

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord (2015) 0.78

On the treatment effect in clinical trials with dropout. J Biopharm Stat (2006) 0.75